Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
The trial's extended results showed that even more weight loss could occur if treatment continues beyond 80 weeks
Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid
For diabetes-specific data, the completed TRANSCEND-T2D-1 trial (537 patients, 40 weeks) is the relevant source: retatrutide reduced HbA1c by up to 2.0% (9mg dose), with 8289% of patients reaching the 120 bpm at rest) The Unknowns: What We're Still Waiting to Learn Full 2-year published safety data: TRIUMPH-1 104-week extension data is available for the BMI 35 subgroup, but full publication of the complete 2-year dataset is pending expected late 2026
It is recommended to be avoided by pregnant and lactating women
US$ 24.78
US$ 27.69
US$ 28.20
US$ 26.34
US$ 20.44
US$ 28.44
US$ 21.79
US$ 24.67
US$ 25.68
US$ 27.34
